Mountain State Medical Policy Bulletin |
Section: | Laboratory |
Number: | L-1 |
Topic: | Pap Smears |
Effective Date: | August 1, 2005 |
Issued Date: | August 1, 2005 |
Date Last Reviewed: | 11/2005 |
Indications and Limitations of Coverage
Pap Smears
Payment may be made for pap smears performed to "rule out" a suspected condition that may be the cause of the patient's symptoms. Cyto-hormonal study (88155) is used primarily to determine the need for, or possible response to, estrogen therapy and to evaluate the hormonal status in patients who have certain types of endocrine problems (e.g., failure to ovulate, possible abnormal sexual development, infertility, etc.) Payment may be made for the cyto-hormonal study (88155) in addition to the pap smear (88142-88154, 88164-88167, 88174, 88175). Claims for pap smears with diagnoses/conditions other than those listed above should be denied on the basis of medical necessity. Individual consideration can be given if this decision is questioned. Pap smears using the ThinPrep method of slide preparation are eligible for payment under codes 88142, 88143, 88174, 88175, G0123, G0124, G0143, G0144, G0145. Pap smears supplemented with the PapNet or AutoPap computerized rescreening are eligible for payment under codes 88147, 88148, 88152, 88154, 88166, 88167, as appropriate. When reported, payment may be made for the physician interpretation (G0124, G0141, P3001, 88141) in addition to the pap smear codes (88142-88154, 88164-88167, 88174, 88175, G0123, G0143, G0144, G0145, G0147, G0148, P3000). When a provider obtains a specimen for a pap smear, then refers that specimen to a laboratory for examination, the cost of obtaining the specimen is included in the allowance for the gynecological examination or evaluation and management service. Payment should be made to the laboratory for the actual pap smear examination. However, if there is a billing arrangement whereby the provider reimburses the laboratory for the pap smear examination, payment can be made to the provider for the pap smear. No payment should be made to the laboratory in this case. See Medical Policy Bulletin V-35 for guidelines on routine/screening pap smears. Speculoscopy Date Last Reviewed: 01/2005 HPV Testing HPV testing of pap smears with normal results for asymptomatic women is considered screening and is covered for patients whose individual or group benefits provide coverage for this test as a routine/screening service. Payment for screening HPV testing is limited to one test per calendar year for women age 30 or older. HPV testing is not intended to substitute for regular routine pap smear screening for cervical cancer. Nor is it intended to screen for women under 30 who have normal pap tests. Although the rate of HPV infection in this group is high, most infections are short-lived and not associated with cervical cancer. Description Pap Smears Speculoscopy HPV Testing HPV testing (87620 or 87621) can be performed on the remaining liquid media used as part of the preparation of monolayer slides (e.g., ThinPrep pap smears). This eliminates the need for the patient to return to the provider’s office for another visit to obtain another sample for HPV testing. In addition, further testing (e.g., colposcopy) and treatment can be initiated sooner. |
|
0031T | 0032T | 87620 | 87621 | 88141 | 88142 |
88143 | 88147 | 88148 | 88150 | 88152 | 88153 |
88154 | 88155 | 88160 | 88161 | 88162 | 88164 |
88165 | 88166 | 88167 | 88174 | 88175 | G0123 |
G0124 | G0141 | G0143 | G0144 | G0145 | G0147 |
G0148 | P3000 | P3001 |
Under the Federal Employee Program, all services that utilize FDA-approved drugs, devices, or biological products are eligible when intended for the treatment of a serious or life-threatening condition and when medically necessary and appropriate for the patient’s condition. Speculoscopy is considered an eligible service when determined medically necessary based on the patient’s condition. |
PRN References 02/1998, New pap smear reporting adopted |